A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
← catalyst calendarNCT06697197 · readout in 868 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
413estimated
Sites
21
Countries
Belgium, Denmark, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-17 | actual | When the study began enrolling |
| Primary completion | 2029-01-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-01-05 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Interventions
- Drug: BMS-986482
- Drug: Nivolumab and rHuPH20 — also filed as BMS-986298
- Drug: Nivolumab/relatlimab/rHuPH20 — also filed as BMS-986213
- Drug: Bevacizumab
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with Adverse Events (AEs) as assessed by National Cancer Institute -Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0)
measured Up to 135 days post last treatment visit
Number of participants with Serious AEs (SAEs) as assessed by NCI-CTCAE v5.0
measured Up to 135 days post last treatment visit
Number of participants with AEs meeting protocol-defined Dose-Limiting Toxicity (DLT) criteria as assessed by NCI-CTCAE v5.0
measured Up to Day 28
Number of participants with AEs leading to discontinuation as assessed by NCI-CTCAE v5.0
measured Up to 135 days post last treatment visit
Number of deaths as assessed by NCI-CTCAE v5.0
measured Through study completion (Up to 4 years)
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed